Stockscreener 앱 받기
9.68
2.33%
0.22
시간 외 거래:
9.68
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Immix Biopharma (NASDAQ:IMMX) Shares Down 8.9%Should You Sell? - MarketBeat
Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial - MSN
Immix Biopharma (NASDAQ:IMMX) Trading Up 6.3%What's Next? - MarketBeat
Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Drops By 13.4% - MarketBeat
Immix Biopharma (NASDAQ:IMMX) Hits New 12-Month HighHere's Why - MarketBeat
Immix Biopharma (IMMX) to Release Earnings on Monday - MarketBeat
Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch - MSN
Immix Biopharma (NASDAQ:IMMX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Analysts Set Immix Biopharma, Inc. (NASDAQ:IMMX) PT at $15.00 - Defense World
IMMX Technical Analysis & ETF Price Forecast - Intellectia AI
Immix Biopharma (NASDAQ:IMMX) Coverage Initiated by Analysts at Citizens Jmp - MarketBeat
Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Citizens initiates Immix Biopharma stock coverage with outperform rating By Investing.com - Investing.com Canada
Citizens initiates Immix Biopharma stock coverage with outperform rating - Investing.com South Africa
Aug Wrap: Does Immix Biopharma Inc have consistent dividend growthMarket Growth Summary & Weekly High Return Stock Forecasts - baoquankhu1.vn
Macro Review: Is Immix Biopharma Inc stock a good pick for beginners2026 Market Overview & Growth Focused Entry Point Reports - baoquankhu1.vn
Why Immix Biopharma Inc. stock could rally in 20262026 Big Picture & Reliable Trade Execution Plans - Naître et grandir
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN
Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
33,035,515 Common Stock of Immix Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 8-MAR-2026. - marketscreener.com
Is Immix Biopharma Inc. stock a top momentum play2025 Big Picture & Detailed Earnings Play Strategies - Naître et grandir
Trade Recap: Is Immix Biopharma Inc in a bullish channel2025 Growth vs Value & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Immix Biopharma to Participate in Upcoming Investor Conferences - GlobeNewswire
Insider Buy: What dividend growth rate does Immix Biopharma Inc offerTrade Risk Assessment & Capital Protection Trading Alerts - baoquankhu1.vn
IMMX Should I Buy - Intellectia AI
IMMX Technical Analysis & Stock Price Forecast - Intellectia AI
IMMX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Investment manager Saturn V holds 6.97% of Immix Biopharma (IMMX) - Stock Titan
Immix Biopharma (IMMX) sees Janus Henderson report 7.4% stake - Stock Titan
Analysts Expect Breakeven For Immix Biopharma, Inc. (NASDAQ:IMMX) Before Long - simplywall.st
Immix Biopharma (NASDAQ:IMMX) Stock Rating Lowered by Wall Street Zen - MarketBeat
Breakeven On The Horizon For Immix Biopharma, Inc. (NASDAQ:IMMX) - Yahoo Finance
Immix Biopharma (NASDAQ:IMMX) Now Covered by Mizuho - MarketBeat
Mizuho Initiates Immix Biopharma at Outperform With $14 Price Target - marketscreener.com
Mizuho initiates coverage of Immix Biopharma (IMMX) with outperform recommendation - MSN
Immix Biopharma (NASDAQ:IMMX) Rating Increased to Hold at Wall Street Zen - MarketBeat
Stock Recap: Whats the MACD signal for Immix Biopharma IncJuly 2025 Selloffs & Safe Entry Point Alerts - baoquankhu1.vn
Is Immix Biopharma Inc. stock a good pick for beginnersJuly 2025 Volume & High Accuracy Investment Entry Signals - mfd.ru
FDA grants breakthrough therapy status to ImmixBio’s amyloidosis drug By Investing.com - Investing.com Canada
Immix Biopharma stock climbs after FDA grants breakthrough therapy status By Investing.com - Investing.com Canada
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 - GlobeNewswire
FDA grants Breakthrough status to NXC-201 in AL amyloidosis with no approved drugs - Stock Titan
Best Biotech Stocks Right Now • Updated Daily - Benzinga
Market Recap: Why Immix Biopharma Inc. stock remains undervaluedQuarterly Market Summary & Comprehensive Market Scan Reports - bollywoodhelpline.com
Is Immix Biopharma Inc stock a good pick for beginnersMarket Trend Report & Safe Entry Point Identification - baoquankhu1.vn
Published on: 2026-01-13 06:33:30 - Улправда
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities - Benzinga
Immix Biopharma (NASDAQ:IMMX) Downgraded to Sell Rating by Wall Street Zen - Defense World
Immix Biopharma to offer and sell up to $750 million in securitiesSEC filing - marketscreener.com
Immix Biopharma — NXC-201’s path to BLA submission - Smartkarma
Why analysts upgrade Immix Biopharma Inc. stock2025 Winners & Losers & Low Risk High Win Rate Picks - ulpravda.ru
Why Immix Biopharma Inc. stock is a must watch in 2025July 2025 Decliners & High Accuracy Investment Entry Signals - Улправда
Why Immix Biopharma Inc. stock remains undervalued2025 Earnings Impact & High Return Trade Guides - Улправда
What technical charts say about Immix Biopharma Inc. stock2025 Support & Resistance & Weekly Watchlist for Hot Stocks - ulpravda.ru
What momentum indicators show for Immix Biopharma Inc. stockRate Hike & Accurate Intraday Trading Signals - ulpravda.ru
Fed Watch: Why analysts upgrade Immix Biopharma Inc stockWeekly Trading Summary & Risk Adjusted Swing Trade Ideas - Bộ Nội Vụ
Swing Trade: Can Immix Biopharma Inc stock surprise with earnings upsidePortfolio Update Report & Consistent Profit Alerts - moha.gov.vn
Why Immix Biopharma Inc stock remains undervaluedJuly 2025 Patterns & Fast Exit and Entry Trade Guides - moha.gov.vn
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Up 27.5% in December - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):